You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,541,448


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,541,448
Title:Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Abstract: The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
Inventor(s): Charmot; Dominique (Campbell, CA), Jacobs; Jeffrey W. (San Mateo, CA), Leadbetter; Michael Robert (San Leandro, CA), Navre; Marc (Belmont, CA), Carreras; Christopher (Belmont, CA), Bell; Noah (Berkeley, CA)
Assignee: Ardelyx, Inc. (Fremont, CA)
Application Number:13/172,394
Patent Claims: 1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure: ##STR00452##

2. The compound of claim 1.

3. A pharmaceutically acceptable salt of the compound of claim 1.

4. The pharmaceutically acceptable salt of claim 3, wherein the pharmaceutically acceptable salt is: ##STR00453##

5. A pharmaceutical composition, wherein the composition comprises: a compound or a pharmaceutically acceptable salt thereof, wherein the compound corresponds to the structure: ##STR00454## and a pharmaceutically acceptable carrier, diluent or excipient.

6. The pharmaceutical composition of claim 5, wherein the pharmaceutically acceptable salt is: ##STR00455##

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.